PubRank

Herbert J Zeh

Author PubWeight™ 130.59‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012 20.08
2 Endogenous HMGB1 regulates autophagy. J Cell Biol 2010 4.71
3 Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg 2013 3.94
4 The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007 3.33
5 High-mobility group box 1 and cancer. Biochim Biophys Acta 2010 3.11
6 RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med 2009 2.56
7 Masquerader: high mobility group box-1 and cancer. Clin Cancer Res 2007 2.40
8 PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev 2012 2.24
9 High-mobility group box 1, oxidative stress, and disease. Antioxid Redox Signal 2011 2.19
10 Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 2011 1.98
11 High-mobility group box 1 is essential for mitochondrial quality control. Cell Metab 2011 1.89
12 Robotic-assisted major pancreatic resection and reconstruction. Arch Surg 2010 1.82
13 Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs 2009 1.79
14 HMGB1 in cancer: good, bad, or both? Clin Cancer Res 2013 1.79
15 Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 2010 1.70
16 Arginine and immunity. J Nutr 2007 1.62
17 Feature Selection for Classification of SELDI-TOF-MS Proteomic Profiles. Appl Bioinformatics 2005 1.56
18 Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol 2008 1.52
19 Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol 2010 1.48
20 NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 2012 1.46
21 Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol 2013 1.46
22 High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007 1.45
23 p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer Res 2012 1.41
24 The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005 1.34
25 EUS-guided fiducial placement for stereotactic body radiotherapy in locally advanced and recurrent pancreatic cancer. Gastrointest Endosc 2010 1.30
26 HMGB1: a novel Beclin 1-binding protein active in autophagy. Autophagy 2010 1.30
27 The expression of the receptor for advanced glycation endproducts (RAGE) is permissive for early pancreatic neoplasia. Proc Natl Acad Sci U S A 2012 1.30
28 High mobility group box 1 (HMGB1) activates an autophagic response to oxidative stress. Antioxid Redox Signal 2011 1.27
29 Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol 2013 1.24
30 250 robotic pancreatic resections: safety and feasibility. Ann Surg 2013 1.23
31 Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2007 1.21
32 Inhibiting systemic autophagy during interleukin 2 immunotherapy promotes long-term tumor regression. Cancer Res 2012 1.17
33 Cytolytic cells induce HMGB1 release from melanoma cell lines. J Leukoc Biol 2006 1.14
34 Integration of KRAS testing in the diagnosis of pancreatic cystic lesions: a clinical experience of 618 pancreatic cysts. Mod Pathol 2013 1.12
35 Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol 2012 1.12
36 Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther 2005 1.11
37 HMGB1 as an autophagy sensor in oxidative stress. Autophagy 2011 1.08
38 High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol 2006 1.07
39 The Receptor for Advanced Glycation End-products (RAGE) protects pancreatic tumor cells against oxidative injury. Antioxid Redox Signal 2011 1.05
40 Assessing the statistical significance of the achieved classification error of classifiers constructed using serum peptide profiles, and a prescription for random sampling repeated studies for massive high-throughput genomic and proteomic studies. Cancer Inform 2005 1.05
41 Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis. Arch Pathol Lab Med 2008 1.05
42 Ethyl pyruvate administration inhibits hepatic tumor growth. J Leukoc Biol 2009 1.04
43 The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. J Immunol 2012 1.03
44 DAMPs and autophagy: cellular adaptation to injury and unscheduled cell death. Autophagy 2013 1.02
45 The redox protein HMGB1 regulates cell death and survival in cancer treatment. Autophagy 2010 1.00
46 Comparative effectiveness of minimally invasive and open distal pancreatectomy for ductal adenocarcinoma. JAMA Surg 2013 0.99
47 Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol 2014 0.99
48 Apoptosis to autophagy switch triggered by the MHC class III-encoded receptor for advanced glycation endproducts (RAGE). Autophagy 2011 0.99
49 AGER/RAGE-mediated autophagy promotes pancreatic tumorigenesis and bioenergetics through the IL6-pSTAT3 pathway. Autophagy 2012 0.98
50 Distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic adenocarcinoma following neoadjuvant therapy. J Gastrointest Surg 2012 0.98
51 Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 2013 0.95
52 Pancreatic lymphoepithelial cysts express CEA and can contain mucous cells: potential pitfalls in the preoperative diagnosis. Mod Pathol 2010 0.94
53 Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins. J Gastrointest Cancer 2012 0.94
54 RAGE regulates autophagy and apoptosis following oxidative injury. Autophagy 2011 0.93
55 Metabolic regulation by HMGB1-mediated autophagy and mitophagy. Autophagy 2011 0.92
56 Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer. Radiat Oncol 2013 0.91
57 Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg 2008 0.91
58 Signet ring cell colorectal carcinoma: a distinct subset of mucin-poor microsatellite-stable signet ring cell carcinoma associated with dismal prognosis. Am J Surg Pathol 2013 0.90
59 Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma. Ann Surg Oncol 2014 0.90
60 Not just nuclear proteins: 'novel' autophagy cancer treatment targets - p53 and HMGB1. Curr Opin Investig Drugs 2008 0.89
61 Robotic-assisted minimally invasive central pancreatectomy: technique and outcomes. J Gastrointest Surg 2013 0.89
62 Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer. J Surg Oncol 2014 0.88
63 The current state of robotic-assisted pancreatic surgery. Nat Rev Gastroenterol Hepatol 2012 0.87
64 Damage associated molecular pattern molecule-induced microRNAs (DAMPmiRs) in human peripheral blood mononuclear cells. PLoS One 2012 0.87
65 Dendritic cells in cancer immunotherapy: vaccines or autologous transplants? Immunol Res 2011 0.86
66 Validation of a prediction rule to maximize curative (R0) resection of early-stage pancreatic adenocarcinoma. HPB (Oxford) 2009 0.86
67 Impact of aggressive histology and location of primary tumor on the efficacy of surgical therapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2013 0.86
68 Direct molecular interactions between HMGB1 and TP53 in colorectal cancer. Autophagy 2012 0.85
69 The utility of the robot in pancreatic resections. Adv Surg 2014 0.84
70 Abdominal compartment syndrome is an early, lethal complication of acute pancreatitis. Am Surg 2013 0.84
71 In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion. J Extra Corpor Technol 2010 0.84
72 Aggressive locoregional surgical therapy for gastric peritoneal carcinomatosis. Ann Surg Oncol 2013 0.83
73 Technical aspects of robotic-assisted pancreaticoduodenectomy (RAPD). J Gastrointest Surg 2010 0.83
74 Mucin as a therapeutic target in pseudomyxoma peritonei. J Surg Oncol 2012 0.82
75 Robotic surgery for benign duodenal tumors. J Gastrointest Surg 2014 0.81
76 Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma. HPB (Oxford) 2013 0.81
77 Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas 2013 0.81
78 Extensive cytoreductive surgery for appendiceal carcinomatosis: morbidity, mortality, and survival. Ann Surg Oncol 2013 0.80
79 Acinar cell cystadenoma of the pancreas: a benign neoplasm or non-neoplastic ballooning of acinar and ductal epithelium? Am J Surg Pathol 2013 0.80
80 The histopathology of PRSS1 hereditary pancreatitis. Am J Surg Pathol 2014 0.79
81 The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow. Pancreas 2015 0.79
82 Pancreaticoduodenectomy in the presence of superior mesenteric venous obstruction. J Gastrointest Surg 2005 0.78
83 Aggressive locoregional management of recurrent peritoneal sarcomatosis. J Surg Oncol 2013 0.78
84 A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion. Ann Surg Oncol 2014 0.77
85 Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei. Ann Surg Oncol 2012 0.77
86 Early detection and staging of adenocarcinoma of the pancreas. Gastroenterol Clin North Am 2007 0.77
87 Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival. Am J Surg Pathol 2015 0.77
88 A Multi-institutional Comparison of Perioperative Outcomes of Robotic and Open Pancreaticoduodenectomy. Ann Surg 2016 0.76
89 Isolated Peripancreatic Necrosis in Acute Pancreatitis Is Infrequent and Leads to Severe Clinical Course Only When Extensive: A Prospective Study From a US Tertiary Center. J Clin Gastroenterol 2016 0.75
90 Increased Serum Insulin Exposure Does Not Affect Age or Stage of Pancreatic Adenocarcinoma Diagnosis in Patients With Diabetes Mellitus. Pancreas 2016 0.75
91 Simultaneous pancreatectomy and liver transplantation: a single-institution experience. HPB (Oxford) 2009 0.75
92 Reply to Letter: "Robot-assisted Minimally Invasive Distal Pancreatectomy Is Superior to the Laparoscopic Technique". Ann Surg 2016 0.75
93 Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol 2012 0.75
94 Outcome analysis of a decade-long experience of isolated hepatic perfusion for unresectable liver metastases at a single institution. Ann Surg 2014 0.75
95 Cyst Gastrostomy and Necrosectomy for the Management of Sterile Walled-Off Pancreatic Necrosis: a Comparison of Minimally Invasive Surgical and Endoscopic Outcomes at a High-Volume Pancreatic Center. J Gastrointest Surg 2015 0.75
96 Grading of Surgeon Technical Performance Predicts Postoperative Pancreatic Fistula for Pancreaticoduodenectomy Independent of Patient-related Variables. Ann Surg 2016 0.75
97 Does obesity affect outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for disseminated mucinous appendiceal neoplasms? Ann Surg Oncol 2014 0.75
98 Array comparative genomic hybridization analysis of solid pseudopapillary neoplasms of the pancreas. Mod Pathol 2008 0.75